文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

洛匹那韦-利托那韦治疗重症Covid-19住院成人的随机对照试验

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
PubMed 文献 · N Engl J Med · 2020-03-18

该随机、对照、开放标签试验纳入199例重症Covid-19住院成人,比较洛匹那韦-利托那韦联合标准治疗与单纯标准治疗。主要终点临床改善时间两组无差异(HR 1.31,95%CI 0.95-1.80),28天死亡率相似(19.2% vs 25.0%),结论为洛匹那韦-利托那韦未显示额外获益。

要点

  • 洛匹那韦-利托那韦未缩短重症Covid-19住院成人的临床改善时间。
  • 28天死亡率两组相似,差值-5.8个百分点(95%CI -17.3至5.7)。
  • 洛匹那韦-利托那韦组胃肠道不良事件更常见,13例(13.8%)因不良事件提前停药。

核心结论

  • 在重症Covid-19住院成人中,洛匹那韦-利托那韦联合标准治疗较单纯标准治疗未观察到获益。

研究设计与样本

  • 随机、对照、开放标签试验,纳入199例实验室确诊SARS-CoV-2感染且需住院的成人患者,按1:1随机分组。
  • 入组条件包括呼吸环境空气时血氧饱和度(Sao2)≤94%或氧分压/吸入氧分数(Pao2/Fio2)<300 mm Hg。
  • 洛匹那韦-利托那韦组99例接受洛匹那韦400 mg和利托那韦100 mg每日两次共14天加标准治疗,标准治疗组100例。

主要发现

  • 主要终点临床改善时间两组无差异(HR 1.31;95%CI 0.95-1.80)。
  • 28天死亡率洛匹那韦-利托那韦组19.2% vs 标准治疗组25.0%(差值-5.8个百分点;95%CI -17.3至5.7)。
  • 各时间点可检测病毒RNA的患者百分比两组相似。
  • 修正意向治疗分析中洛匹那韦-利托那韦组中位临床改善时间较标准治疗组缩短1天(HR 1.39;95%CI 1.00-1.91)。
  • 洛匹那韦-利托那韦组胃肠道不良事件更常见,标准治疗组严重不良事件更常见;13例(13.8%)因不良事件提前停用洛匹那韦-利托那韦。

临床怎么用

  • 重症Covid-19住院成人不应在标准治疗外常规加用洛匹那韦-利托那韦。

局限性

  • 未来针对重症患者的试验可能有助于确认或排除治疗获益的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. METHODS: We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first. RESULTS: A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group. Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80). Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir-ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir-ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events. CONCLUSIONS: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020. PMID: 32187464. doi:10.1056/NEJMoa2001282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。